Business Description
Cabaletta Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US12674W1099
Share Class Description:
MEX:CABA: Ordinary SharesTotal Employee Number:
158Description
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.41 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -4.4 | |||||
3-Year EPS without NRI Growth Rate | -5.1 | |||||
3-Year FCF Growth Rate | 0.2 | |||||
3-Year Book Growth Rate | -32 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.86 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.95 | |||||
Quick Ratio | 2.95 | |||||
Cash Ratio | 2.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -50.6 | |||||
Shareholder Yield % | -27.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -133.94 | |||||
ROA % | -98.26 | |||||
ROIC % | -330.69 | |||||
3-Year ROIIC % | -254.75 | |||||
ROC (Joel Greenblatt) % | -752.74 | |||||
ROCE % | -127.32 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.35 | |||||
Price-to-Tangible-Book | 3.34 | |||||
EV-to-EBIT | -2.3 | |||||
EV-to-Forward-EBIT | -0.06 | |||||
EV-to-EBITDA | -2.32 | |||||
EV-to-Forward-EBITDA | -0.06 | |||||
EV-to-FCF | -2.91 | |||||
| Price-to-Net-Current-Asset-Value | 4.44 | |||||
| Price-to-Net-Cash | 4.86 | |||||
Earnings Yield (Greenblatt) % | -43.53 | |||||
FCF Yield % | -29.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cabaletta Bio Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -35.271 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 24.05 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | 0.376669 | ||
| 20-Day SMA (MXN) | 57.089 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 54.5 - 71.76 | ||
| Shares Outstanding (Mil) | 163.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cabaletta Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cabaletta Bio Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 36 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 71.76 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 71.76 (+0.00%) | ||
| Annual report for 2025 | 2026-03-23 | 71.76 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 71.76 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 11:10 | 71.76 (+0.00%) | ||
| Guidance call for 2026 | 2026-02-12 09:30 | 71.76 (+0.00%) | ||
| Guidance call for 2025 | 2025-12-03 13:45 | 71.76 (+0.00%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-02 08:20 | 71.76 (+0.00%) |
Show
Entries
Cabaletta Bio Inc Frequently Asked Questions
What is Cabaletta Bio Inc(MEX:CABA)'s stock price today?
The current price of MEX:CABA is MXN54.50. The 52 week high of MEX:CABA is MXN71.76 and 52 week low is MXN54.50.
When is next earnings date of Cabaletta Bio Inc(MEX:CABA)?
The next earnings date of Cabaletta Bio Inc(MEX:CABA) is 2026-08-07 Est..
Does Cabaletta Bio Inc(MEX:CABA) pay dividends? If so, how much?
Cabaletta Bio Inc(MEX:CABA) does not pay dividend.
Press Release
Articles on Cabaletta Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers